"{\n \"business_address\": \"345 PARK AVE, NEW YORK, NY 10154\", \n \"business_phone_no\": \"2125464000\", \n \"ceo\": \"Giovanni Caforio\", \n \"cik\": \"0000014272\", \n \"company_url\": \"www.bms.com\", \n \"employees\": 25000, \n \"entity_legal_form\": null, \n \"entity_status\": null, \n \"hq_address1\": null, \n \"hq_address2\": null, \n \"hq_address_city\": null, \n \"hq_address_postal_code\": null, \n \"hq_country\": \"United States of America\", \n \"hq_state\": \"New York\", \n \"inc_country\": \"United States of America\", \n \"inc_state\": \"Delaware\", \n \"industry_category\": \"Drugs\", \n \"industry_group\": \"Drug Manufacturers - Major\", \n \"latest_filing_date\": \"2017-07-27\", \n \"legal_name\": \"BRISTOL MYERS SQUIBB CO\", \n \"lei\": \"HLYYNH7UQUORYSJQCN42\", \n \"long_description\": \"Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaborations with Portola Pharmaceuticals, Inc. to develop and commercialize andexanet alfa, an investigational agent; Apexigen, Inc. to evaluate Opdivo in combination with APX005M in patients with solid tumors; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.\", \n \"mailing_address\": \"345 PARK AVE, NEW YORK, NY 10154\", \n \"name\": \"Bristol-Myers Squibb Co\", \n \"sector\": \"Healthcare\", \n \"securities\": [\n  {\n   \"composite_figi\": \"BBG000DQLV23\", \n   \"composite_figi_ticker\": \"BMY:US\", \n   \"currency\": \"USD\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XNYS\", \n   \"figi\": \"BBG000DQLV23\", \n   \"figi_exch_cntry\": \"US\", \n   \"figi_ticker\": \"BMY:US\", \n   \"figi_uniqueid\": \"EQ0010022500001000\", \n   \"last_crsp_adj_date\": \"2017-10-05\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XNYS\", \n   \"primary_listing\": true, \n   \"security_name\": \"BRISTOL-MYERS SQUIBB CO\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8N8J6\", \n   \"stock_exchange\": \"NYSE\", \n   \"ticker\": \"BMY\"\n  }, \n  {\n   \"composite_figi\": \"BBG006TLNGD3\", \n   \"composite_figi_ticker\": \"BMY:SW\", \n   \"currency\": \"CHF\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBRN\", \n   \"figi\": \"BBG006TLNGL4\", \n   \"figi_exch_cntry\": \"BW\", \n   \"figi_ticker\": \"BMY:BW\", \n   \"figi_uniqueid\": \"EQ0000000036701505\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBRN\", \n   \"primary_listing\": false, \n   \"security_name\": \"BRISTOL-MYERS SQUIBB CO.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8N8J6\", \n   \"stock_exchange\": \"BRN\", \n   \"ticker\": \"US1101221083\"\n  }, \n  {\n   \"composite_figi\": \"BBG000K1T0N7\", \n   \"composite_figi_ticker\": \"BRM:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XHAM\", \n   \"figi\": \"BBG000K1T7F1\", \n   \"figi_exch_cntry\": \"GH\", \n   \"figi_ticker\": \"BRM:GH\", \n   \"figi_uniqueid\": \"EQ0010022500001002\", \n   \"last_crsp_adj_date\": \"2017-10-05\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XHAM\", \n   \"primary_listing\": false, \n   \"security_name\": \"BRISTOL-MYERS SQUIBB CO.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8N8J6\", \n   \"stock_exchange\": \"HAM\", \n   \"ticker\": \"BRM\"\n  }, \n  {\n   \"composite_figi\": \"BBG000K1T0N7\", \n   \"composite_figi_ticker\": \"BRM:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XDUS\", \n   \"figi\": \"BBG000K1T1N5\", \n   \"figi_exch_cntry\": \"GD\", \n   \"figi_ticker\": \"BRM:GD\", \n   \"figi_uniqueid\": \"EQ0010022500001002\", \n   \"last_crsp_adj_date\": \"2017-10-05\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XDUS\", \n   \"primary_listing\": false, \n   \"security_name\": \"BRISTOL-MYERS SQUIBB CO.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8N8J6\", \n   \"stock_exchange\": \"DUS\", \n   \"ticker\": \"BRM\"\n  }, \n  {\n   \"composite_figi\": \"BBG000K1T0N7\", \n   \"composite_figi_ticker\": \"BRM:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XMUN\", \n   \"figi\": \"BBG000K1T3X0\", \n   \"figi_exch_cntry\": \"GM\", \n   \"figi_ticker\": \"BRM:GM\", \n   \"figi_uniqueid\": \"EQ0010022500001002\", \n   \"last_crsp_adj_date\": \"2017-10-05\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XMUN\", \n   \"primary_listing\": false, \n   \"security_name\": \"BRISTOL-MYERS SQUIBB CO.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8N8J6\", \n   \"stock_exchange\": \"MUN\", \n   \"ticker\": \"BRM\"\n  }, \n  {\n   \"composite_figi\": \"BBG000K1T0N7\", \n   \"composite_figi_ticker\": \"BRM:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSTU\", \n   \"figi\": \"BBG000K1T333\", \n   \"figi_exch_cntry\": \"GS\", \n   \"figi_ticker\": \"BRM:GS\", \n   \"figi_uniqueid\": \"EQ0010022500001002\", \n   \"last_crsp_adj_date\": \"2017-10-05\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSTU\", \n   \"primary_listing\": false, \n   \"security_name\": \"BRISTOL-MYERS SQUIBB CO.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8N8J6\", \n   \"stock_exchange\": \"STU\", \n   \"ticker\": \"BRM\"\n  }, \n  {\n   \"composite_figi\": \"BBG000K1T0N7\", \n   \"composite_figi_ticker\": \"BRM:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XETR\", \n   \"figi\": \"BBG000K1T2J8\", \n   \"figi_exch_cntry\": \"GY\", \n   \"figi_ticker\": \"BRM:GY\", \n   \"figi_uniqueid\": \"EQ0010022500001002\", \n   \"last_crsp_adj_date\": \"2017-10-05\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XETR\", \n   \"primary_listing\": false, \n   \"security_name\": \"BRISTOL-MYERS SQUIBB CO.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8N8J6\", \n   \"stock_exchange\": \"XETRA\", \n   \"ticker\": \"BRM\"\n  }, \n  {\n   \"composite_figi\": \"BBG000K1T0N7\", \n   \"composite_figi_ticker\": \"BRM:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XFRA\", \n   \"figi\": \"BBG000K1T173\", \n   \"figi_exch_cntry\": \"GF\", \n   \"figi_ticker\": \"BRM:GF\", \n   \"figi_uniqueid\": \"EQ0010022500001002\", \n   \"last_crsp_adj_date\": \"2017-10-05\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XFRA\", \n   \"primary_listing\": false, \n   \"security_name\": \"BRISTOL-MYERS SQUIBB CO\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8N8J6\", \n   \"stock_exchange\": \"FRA\", \n   \"ticker\": \"BRM\"\n  }, \n  {\n   \"composite_figi\": \"BBG006TLNGD3\", \n   \"composite_figi_ticker\": \"BMY:SW\", \n   \"currency\": \"CHF\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSWX\", \n   \"figi\": \"BBG006TLNGG0\", \n   \"figi_exch_cntry\": \"SE\", \n   \"figi_ticker\": \"BMY:SE\", \n   \"figi_uniqueid\": \"EQ0000000036701505\", \n   \"last_crsp_adj_date\": \"2017-09-29\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSWX\", \n   \"primary_listing\": false, \n   \"security_name\": \"BRISTOL-MYERS SQUIBB CO\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8N8J6\", \n   \"stock_exchange\": \"SIX\", \n   \"ticker\": \"BMY\"\n  }, \n  {\n   \"composite_figi\": \"BBG000L47KD1\", \n   \"composite_figi_ticker\": \"BMY*:MM\", \n   \"currency\": \"MXN\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XMEX\", \n   \"figi\": \"BBG000L47L12\", \n   \"figi_exch_cntry\": \"MM\", \n   \"figi_ticker\": \"BMY*:MM\", \n   \"figi_uniqueid\": \"EQ0000000001393282\", \n   \"last_crsp_adj_date\": \"2017-10-05\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XMEX\", \n   \"primary_listing\": false, \n   \"security_name\": \"BRISTOL-MYERS SQUIBB CO\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8N8J6\", \n   \"stock_exchange\": \"MEX\", \n   \"ticker\": \"BMY\"\n  }, \n  {\n   \"composite_figi\": \"BBG000K1T0N7\", \n   \"composite_figi_ticker\": \"BRM:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBER\", \n   \"figi\": \"BBG000K1T5H3\", \n   \"figi_exch_cntry\": \"GB\", \n   \"figi_ticker\": \"BRM:GB\", \n   \"figi_uniqueid\": \"EQ0010022500001002\", \n   \"last_crsp_adj_date\": \"2017-10-05\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBER\", \n   \"primary_listing\": false, \n   \"security_name\": \"BRISTOL-MYERS SQUIBB CO.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S8N8J6\", \n   \"stock_exchange\": \"BER\", \n   \"ticker\": \"BRM\"\n  }\n ], \n \"short_description\": \"Bristol-Myers Squibb Co. operates as a biopharmaceutical company, which engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.\", \n \"sic\": 2834, \n \"standardized_active\": true, \n \"stock_exchange\": \"NYSE\", \n \"template\": \"industrial\", \n \"ticker\": \"BMY\"\n}"